7 July 2021 - Final guidance published after appeal.

Nivolumab is recommended as an option for the treatment of adults with locally advanced or metastatic non-squamous non-small-cell lung cancer after the use of chemotherapy, only if:

• Their tumours are PD-L1 positive
• It is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses
• They have not had a PD-1 or PD-L1 inhibitor before

Read NICE technology appraisal guidance for nivolumab